JP2024050588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024050588A5 JP2024050588A5 JP2024001510A JP2024001510A JP2024050588A5 JP 2024050588 A5 JP2024050588 A5 JP 2024050588A5 JP 2024001510 A JP2024001510 A JP 2024001510A JP 2024001510 A JP2024001510 A JP 2024001510A JP 2024050588 A5 JP2024050588 A5 JP 2024050588A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- cancer
- promoter
- pcpv
- antibody against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 43
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102100034256 Mucin-1 Human genes 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- DQECFVGMGBQCPA-GLCLSGQWSA-N 2,2-dimethylpropanoyloxymethyl (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydron;chloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DQECFVGMGBQCPA-GLCLSGQWSA-N 0.000 claims 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 108700005077 Viral Genes Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 230000002601 intratumoral effect Effects 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 230000032823 cell division Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 238000000315 cryotherapy Methods 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 238000002428 photodynamic therapy Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 241000621172 Pseudocowpox virus Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009134 cell regulation Effects 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305237 | 2018-03-07 | ||
| EP18305237.2 | 2018-03-07 | ||
| EP18306424.5 | 2018-10-31 | ||
| EP18306424 | 2018-10-31 | ||
| PCT/EP2019/055744 WO2019170820A1 (en) | 2018-03-07 | 2019-03-07 | Parapoxvirus vectors |
| JP2020546320A JP2021516957A (ja) | 2018-03-07 | 2019-03-07 | パラポックスウイルスベクター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546320A Division JP2021516957A (ja) | 2018-03-07 | 2019-03-07 | パラポックスウイルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024050588A JP2024050588A (ja) | 2024-04-10 |
| JP2024050588A5 true JP2024050588A5 (https=) | 2024-04-30 |
Family
ID=65628796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546320A Pending JP2021516957A (ja) | 2018-03-07 | 2019-03-07 | パラポックスウイルスベクター |
| JP2024001510A Pending JP2024050588A (ja) | 2018-03-07 | 2024-01-09 | パラポックスウイルスベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546320A Pending JP2021516957A (ja) | 2018-03-07 | 2019-03-07 | パラポックスウイルスベクター |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12377142B2 (https=) |
| EP (1) | EP3762020A1 (https=) |
| JP (2) | JP2021516957A (https=) |
| CN (1) | CN112512560A (https=) |
| AU (1) | AU2019229653B2 (https=) |
| BR (1) | BR112020018117A2 (https=) |
| CA (1) | CA3093093A1 (https=) |
| IL (1) | IL277161A (https=) |
| MX (1) | MX2020009262A (https=) |
| WO (1) | WO2019170820A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021258008A1 (en) * | 2020-06-19 | 2021-12-23 | Immunacor Llc | Compositions and methods for treating and preventing viral infection |
| WO2023083951A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN116121207B (zh) * | 2023-02-08 | 2025-12-12 | 华南农业大学 | 一种表达猪圆环病毒3型Cap蛋白的重组羊口疮病毒及其制备方法和应用 |
| WO2024178260A2 (en) * | 2023-02-22 | 2024-08-29 | Cornell University | Systems and methods for heterologous gene expression by poxvirus vectors |
| CN116897887A (zh) * | 2023-07-31 | 2023-10-20 | 湖南中医药大学 | 一种病毒性哮喘动物模型的构建方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| CA2247336C (en) | 1996-02-28 | 2008-06-17 | Bayer Aktiengesellschaft | Parapoxviruses containing foreign dna, their production and their use in vaccines |
| EP0904393A4 (en) | 1996-03-29 | 1999-09-08 | Univ Otago | PARAPOXVIRUS VECTORS |
| CA2261989C (en) | 1996-07-25 | 2008-09-30 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1012276A2 (en) | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| AU1071701A (en) | 1999-09-29 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| KR20040074067A (ko) | 2001-12-10 | 2004-08-21 | 버베리안 노딕 에이/에스 | 폭스바이러스를 포함하는 제형 및 폭스바이러스를포함하는 안정한 조성물을 제조하기 위한 방법 |
| CA2431349A1 (en) * | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| US7262045B2 (en) | 2003-02-25 | 2007-08-28 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| WO2005007857A1 (en) | 2003-07-21 | 2005-01-27 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
| CA2573204C (en) | 2004-07-13 | 2011-09-20 | Aicuris Gmbh & Co. Kg | Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| CN101360821A (zh) | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| HUE030533T2 (hu) * | 2006-06-20 | 2017-05-29 | Transgene Sa | Eljárás poxvírusok és poxvírus-készítmények elõállítására |
| WO2008092854A2 (en) | 2007-01-30 | 2008-08-07 | Transgene S.A. | Papillomavirus e2 polypeptide used for vaccination |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| PT103865A (pt) | 2007-10-25 | 2009-05-15 | Univ De Coimbra | Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção |
| CA2705869C (en) | 2007-11-19 | 2012-10-30 | Philippe Erbs | Poxviral oncolytic vectors |
| CN103080415B (zh) | 2010-07-01 | 2016-08-10 | 诺维信公司 | 纸浆的漂白 |
| RU2013102413A (ru) | 2010-07-20 | 2014-08-27 | ЭйЭйч ЮЭсЭй 42 ЭлЭлСи | Парапоксвирусные векторы |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| AU2015357225B2 (en) | 2014-12-01 | 2020-04-09 | Transgene Sa | Stable liquid vaccinia virus formulations |
| ES3011733T3 (en) * | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| DE102015111756A1 (de) | 2015-07-20 | 2017-01-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Rekombinanter Orf-Virus-Vektor |
| WO2018031694A1 (en) | 2016-08-09 | 2018-02-15 | City Of Hope | Chimeric poxvirus compositions and uses thereof |
-
2019
- 2019-03-07 JP JP2020546320A patent/JP2021516957A/ja active Pending
- 2019-03-07 AU AU2019229653A patent/AU2019229653B2/en active Active
- 2019-03-07 WO PCT/EP2019/055744 patent/WO2019170820A1/en not_active Ceased
- 2019-03-07 BR BR112020018117-0A patent/BR112020018117A2/pt unknown
- 2019-03-07 EP EP19708331.4A patent/EP3762020A1/en active Pending
- 2019-03-07 CN CN201980030479.4A patent/CN112512560A/zh active Pending
- 2019-03-07 MX MX2020009262A patent/MX2020009262A/es unknown
- 2019-03-07 CA CA3093093A patent/CA3093093A1/en active Pending
- 2019-03-07 US US16/978,219 patent/US12377142B2/en active Active
-
2020
- 2020-09-06 IL IL277161A patent/IL277161A/en unknown
-
2024
- 2024-01-09 JP JP2024001510A patent/JP2024050588A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050588A5 (https=) | ||
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| Maverakis et al. | Metastatic melanoma–a review of current and future treatment options | |
| US10646557B2 (en) | Vaccine composition | |
| JP2021516957A5 (https=) | ||
| Cemazar et al. | Cancer electrogene therapy with interleukin-12 | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| Hernandez-Alcoceba et al. | Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12 | |
| Rothschild et al. | Immunotherapy in head and neck cancer-scientific rationale, current treatment options and future directions | |
| Wang et al. | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | |
| CA3073310A1 (en) | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody | |
| US20210268087A1 (en) | Major histocompatibility complex class ii-expressing cancer cell vaccine and methods of use for producing integrated immune responses | |
| Velasco et al. | Tumour microenvironment and heterotypic interactions in pancreatic cancer | |
| Rafiq et al. | Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects | |
| JPWO2019243847A5 (https=) | ||
| Izzi et al. | Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains | |
| JPWO2019170820A5 (https=) | ||
| JP7827646B2 (ja) | がん免疫療法に対する応答性を決定する方法 | |
| WO2006060790A2 (en) | Neoadjuvant genetic compositions and methods | |
| O'Neal et al. | Natural and Engineered Cytokines as Cancer Therapeutics | |
| Palathingal et al. | Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review | |
| RU2025100052A (ru) | Рекомбинантный вирус, экспрессирующий интерлейкин-12 | |
| JPWO2022109133A5 (https=) | ||
| RU2021106806A (ru) | Химерный онколитический вирус герпеса, стимулирующий противоопухолевый иммунный ответ | |
| HK40088320A (zh) | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |